COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,594 Articles (22,905 medRxiv, 8,689 bioRxiv)

Most recent first Previous |  Page 2638: Articles 26371-26380  | Next

In silico multi-epitope vaccine against covid19 showing effective interaction with HLA-B*15:03
Faiza, M., Abdullah, T., Calderon-Tantalean, J. F., Upadhyay, M. R., Abdelmoneim, A. H., Akram, F., Thakur, B. S., Abdulaziz, I., Ononamadu, C. J., Ghoraba, D. A., Munawar, S., Faruque, M. F. I., Kigen, C., Sharma, A., Kumar, A., Khalid, A., Gharip, A., Gupta, A., Manikumar, M., Chaudhary, U.
10.1101/2020.06.10.143545 — Posted: 2020-06-14 Discussion: Onsite
The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2
Zimniak, M., Kirschner, L., Hilpert, H., Seibel, J., Bodem, J.
10.1101/2020.06.14.150490 — Posted: 2020-06-14 Discussion: Onsite
Calreticulin co-expression supports high level production of a recombinant SARS-CoV-2 spike mimetic in Nicotiana benthamiana
Margolin, E. A., Verbeek, M., Meyers, A., Chapman, R., Williamson, A.-L., Rybicki, E.
10.1101/2020.06.14.150458 — Posted: 2020-06-14 Discussion: Onsite
SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease
Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., Purpura, L. J., Laracy, J. C., Yu, J., Sodroski, J., Huang, Y., Ho, D. D.
10.1101/2020.06.13.150250 — Posted: 2020-06-14
Single-cell screening of SARS-CoV-2 target cells in pets, livestock, poultry and wildlife
Chen, D., Sun, J., Zhu, J., Ding, X., Lan, T., Zhu, L., Xiang, R., Ding, P., Wang, H., Wang, X., Wu, W., Qiu, J., Wang, S., Li, H., An, F., Bao, H., Zhang, L., Han, L., Zhu, Y., Wang, X., Wang, F., Yuan, Y., Wu, W., Sun, C., Lu, H., Wu, J., Sun, X., Zhang, S., Sahu, S. K., Chen, H., Fang, D., Luo, L., Zeng, Y., Wu, Y., Cui, Z., He, Q., Jiang, S., Ma, X., Feng, W., Xu, Y., Li, F., Liu, Z., Chen, L., Chen, F., Jin, X., Qiu, W., Yang, H., Wang, J., Hua, Y., Liu, Y., Liu, H., Xu, X.
10.1101/2020.06.13.149690 — Posted: 2020-06-14
X-206 is a potent and selective inhibitor of SARS-CoV-2 infection in vitro
Svenningsen, E. B., Jensen, J. T., Cadanet, J. B., Liu, H., Lin, S., Villameriel, J. M., Paludan, S. R., Holm, C. K., Poulsen, T. B.
10.1101/2020.06.14.149153 — Posted: 2020-06-14
How to better communicate exponential growth of infectious diseases
Schonger, M., Sele, D.
10.1101/2020.06.12.20129114 — Posted: 2020-06-14
COVID-19 Deaths: Which Explanatory Variables Matter the Most?
Riley, P., Riley, A., Turtle, J., Ben-Nun, M.
10.1101/2020.06.11.20129007 — Posted: 2020-06-14 Discussion: Onsite
Multiplex Isothermal Amplification Coupled with Nanopore Sequencing for Rapid Detection and Mutation Surveillance of SARS-CoV-2
Bi, C., Ramos-Mandujano, G., Hala, S., Xu, J., Mfarrej, S., Alofi, F. S., Khogeer, A., Hashem, A. M., Almontashiri, N. A. M., Pain, A., Li, M.
10.1101/2020.06.12.20129247 — Posted: 2020-06-14
Global research trend in the treatment of the new Coronavirus diseases (COVID-19) : bibliometric analysis.
Mbogning Fonkou, M. D., YACOUBA, A.
10.1101/2020.06.13.20122762 — Posted: 2020-06-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).